비임상시험 시장

Global Non-Clinical Trials Market to Reach US$15.6 Billion by 2030

The global market for Non-Clinical Trials estimated at US$11.0 Billion in the year 2024, is expected to reach US$15.6 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Pharmacodynamics Studies, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$8.4 Billion by the end of the analysis period. Growth in the Pharmacokinetics Studies segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 9.3% CAGR

The Non-Clinical Trials market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.1 Billion by the year 2030 trailing a CAGR of 9.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Non Clinical Trials Market - Key Trends & Drivers Summarized

Why Are Non Clinical Trials Foundational to Drug Development?

Non clinical trials, also known as preclinical studies, are essential steps in drug and medical device development. These trials involve laboratory and animal testing designed to assess safety, pharmacology, toxicity, and bioavailability before human exposure. By exploring dose ranges, side effects, and mechanism of action, developers can make informed decisions regarding candidate selection and optimal delivery methods. This upfront evaluation helps reduce failure rates in later stages, saving both time and costs in the development cycle.

Regulatory authorities require robust non clinical data to support applications for human trials. Studies often include acute and chronic toxicity, genotoxicity, reproductive toxicity, and carcinogenicity assessments. Clinicians rely on this foundational data to design trial protocols, establish dosing regimens, and anticipate potential safety concerns. A thorough non clinical package also increases confidence among investors and partners during early-stage funding or licensing discussions.

How Are Advances in Technology Enhancing Preclinical Study Precision?

Emerging tools and methodologies are significantly refining non clinical trials. In vitro organ-on-chip models and 3D cell cultures now allow more accurate replication of human organ responses, reducing reliance on animal testing. These systems help uncover human-specific toxic effects earlier, improving predictive value. Meanwhile, high-content imaging, microdosing, and advanced pharmacokinetic modelling enable precise exposure analysis and mechanistic insights at smaller scale and cost.

Genetically engineered animals and CRISPR edited models have improved disease modeling for oncology, neurology, and rare conditions. These models better mimic human pathophysiology, providing more relevant safety and efficacy data. Automation and AI driven analysis tools are also streamlining data collection from behavioral, biochemical, and histopathological endpoints. As non clinical research becomes more data driven, developers can adapt study designs in real time, enhance reproducibility, and optimize resource use.

What Trends Are Shaping Outsourcing and CRO Engagement?

Non clinical trials are increasingly outsourced to specialized Contract Research Organizations (CROs) worldwide. Sponsors seek CROs with GLP certified facilities, disease specific expertise, and high throughput capacity. The shift toward integrated services means many organizations now prefer full package CROs offering in vitro, in vivo, toxicology, and pharmacology studies under one roof. This consolidation supports better data consistency, reduced hand offs, and streamlined project management.

Global reach and environmental sensitivity are motivating sponsors to select CRO partners with geographic diversity and local regulatory knowledge. Asia and Eastern Europe are gaining attention due to lower costs, shorter study timelines, and regional specialization. CROs are also forming partnerships with biotech incubators and academic labs to leverage novel models or emerging technology platforms. This dynamic ecosystem is helping non clinical research adapt more rapidly to new therapeutic modalities and regulatory expectations.

Growth in the non clinical trials market is driven by several factors.

Rising investment in drug discovery, particularly for biologics, gene therapies, and precision medicines, is fueling demand for complex non clinical studies. Regulatory emphasis on rigorous safety evaluation, including advanced toxicology and disease-specific modeling, is encouraging sponsors to engage more comprehensive preclinical packages. Adoption of organ-on-chip systems, CRISPR-modified animal models, and in silico simulations is expanding testing capabilities and efficiency. Growing reliance on outsourced capabilities, especially from specialized and GLP-compliant CROs with global footprints, is changing how preclinical projects are managed. Informed by the broader move toward alternative testing platforms, environmental and ethical pressure is reinforcing innovation in animal-reduction strategies. These combined trends are shaping a robust growth trajectory for the non clinical trials market.

SCOPE OF STUDY:

The report analyzes the Non-Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Study Type (Pharmacodynamics Studies, Pharmacokinetics Studies, Toxicology Studies); Test (In-Silico Test, In-Vitro Test, In-Vivo Test); Therapeutic Area (Oncology, Cardiovascular, Neurology, Immunology, Other Therapeutic Areas); End-Use (Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Altasciences
• Antibody Solutions
• ApconiX
• BIOQUAL, Inc.
• Charles River Laboratories
• Clinipace
• CMIC Group
• ERBC Group
• Eurofins Scientific
• H1 Inc.
• ICON plc
• Labcorp Drug Development (Covance)
• Medpace
• Melior Discovery
• PharmaLegacy Laboratories
• PPD, Inc. (Thermo Fisher Scientific)
• PSI
• SGS SA
• Stillmeadow
• Symeres
• WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Non-Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Drug Development Costs Drive Interest in Non-Clinical Trials for Early Safety and Efficacy Assessment
  • Stringent Global Regulatory Requirements Spur Demand for Robust Preclinical Data Packages
  • Growth in Biologics and Cell-Based Therapies Expands Scope for Non-Clinical Safety and Toxicity Studies
  • Increased Use of In Vitro and In Vivo Models Strengthens Predictive Value of Non-Clinical Research
  • Focus on Reducing Animal Testing Encourages Adoption of Alternative and 3D Cell Culture Models
  • Integration of Computational Toxicology and In Silico Modeling Enhances Trial Efficiency and Cost Reduction
  • Adoption of High-Throughput Screening Technologies Accelerates Early-Stage Drug Candidate Evaluation
  • Pharmaceutical Industry Shift Toward Targeted Therapies Spurs Use of Non-Clinical Biomarker Validation
  • Use of CROs for Outsourced Non-Clinical Studies Grows Due to Cost Efficiency and Specialized Expertise
  • Rising Complexity of Drug Molecules and Delivery Systems Drives Innovation in Preclinical Study Design
  • Advancements in Imaging and Omics Technologies Improve Data Quality in Non-Clinical Trials
  • Emphasis on Immunotoxicology and Genetic Toxicology Studies Expands Regulatory Acceptance Scope
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Non-Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Non-Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Non-Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Non-Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Pharmacodynamics Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Pharmacodynamics Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Pharmacodynamics Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Pharmacokinetics Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Pharmacokinetics Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Pharmacokinetics Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Toxicology Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Academic & Government Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Academic & Government Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for In-Silico Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for In-Silico Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for In-Silico Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for In-Vitro Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for In-Vitro Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for In-Vitro Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for In-Vivo Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for In-Vivo Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for In-Vivo Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: USA 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Canada 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• JAPAN
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Japan 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Japan 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Japan 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• CHINA
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 86: China Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: China 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: China 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: China 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: China 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• EUROPE
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Non-Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Non-Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Europe 16-Year Perspective for Non-Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Europe 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• FRANCE
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 113: France Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: France 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: France 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: France 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: France 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• GERMANY
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Germany 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Germany 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Germany 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Italy 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Italy 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Italy 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 149: UK Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: UK 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: UK 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: UK 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Spain 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Spain 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Spain 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Russia 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Russia 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Russia 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Non-Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Non-Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 16-Year Perspective for Non-Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Australia 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Australia 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Australia 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• INDIA
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 224: India Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: India 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: India 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: India 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: India 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: South Korea 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: South Korea 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: South Korea 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Non-Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Non-Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Latin America 16-Year Perspective for Non-Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Latin America 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Argentina 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Argentina 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Argentina 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Brazil 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Brazil 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Brazil 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Mexico 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Mexico 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Mexico 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Non-Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Non-Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: Middle East 16-Year Perspective for Non-Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 337: Middle East 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 340: Iran 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 346: Iran 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 349: Iran 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 352: Israel 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 358: Israel 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 361: Israel 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 376: UAE 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 382: UAE 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 385: UAE 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030
• AFRICA
  • Non-Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Non-Clinical Trials by Study Type - Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 400: Africa 16-Year Perspective for Non-Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Pharmacodynamics Studies, Pharmacokinetics Studies and Toxicology Studies for the Years 2014, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Non-Clinical Trials by Therapeutic Area - Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Non-Clinical Trials by Therapeutic Area - Percentage Breakdown of Value Sales for Immunology, Other Therapeutic Areas, Oncology, Cardiovascular and Neurology for the Years 2014, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Non-Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 406: Africa 16-Year Perspective for Non-Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CROs End-Use, Academic & Government Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Non-Clinical Trials by Test - In-Silico Test, In-Vitro Test and In-Vivo Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 409: Africa 16-Year Perspective for Non-Clinical Trials by Test - Percentage Breakdown of Value Sales for In-Silico Test, In-Vitro Test and In-Vivo Test for the Years 2014, 2025 & 2030

IV. COMPETITION